The Potential for Circulating Tumor Cells in Pancreatic Cancer Management. by Pimienta, Michael et al.
UCLA
UCLA Previously Published Works
Title


















eScholarship.org Powered by the California Digital Library
University of California
REVIEW
published: 02 June 2017
doi: 10.3389/fphys.2017.00381













This article was submitted to
Gastrointestinal Sciences,
a section of the journal
Frontiers in Physiology
Received: 30 January 2017
Accepted: 22 May 2017
Published: 02 June 2017
Citation:
Pimienta M, Edderkaoui M, Wang R
and Pandol S (2017) The Potential for
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Pancreatic cancer is one the most lethal malignancies. Only a small proportion of patients
with this disease benefit from surgery. Chemotherapy provides only a transient benefit.
Though much effort has gone into finding new ways for early diagnosis and treatment,
average patient survival has only been improved in the order of months. Circulating tumor
cells (CTCs) are shed from primary tumors, including pre-malignant phases. These cells
possess information about the genomic characteristics of their tumor source in situ, and
their detection and characterization holds potential in early cancer diagnosis, prognosis,
and treatment. Liquid Biopsies present an alternative to tumor biopsy that are hard to
sample. Below we summarize current methods of CTC detection, the current literature
on CTCs in pancreatic cancer, and future perspectives.
Keywords: circulating tumor cells, pancreatic cancer, pancreatic adenocarcinoma, metastasis, epithelial to
mesenchymal transition, mesenchymal to epithelial transitions
INTRODUCTION
Virtually all cancers have the potential to metastasize, and metastatic disease comes about from a
series of events involving the interplay between primary tumor cells and their microenvironment.
The end result is the dissemination and growth of tumor cells in new tissue environments. First
described in the literature in the nineteenth century by British surgeon James Paget, metastatic
disease largely remains an unsolved worldwide public health concern today—metastasis accounts
for more than 90% of cancer-related deaths (Ashworth, 1869; Spano et al., 2012).
We now know that metastasis is an “extremely complex” multistep process. Tumor cells must
advance through an invasion-metastasis cascade. In order to produce clinically detectable lesions,
primary tumor cells need to progressively intravasate through the basal membrane into the systemic
or lymphatic circulation, survive in the circulatory environment, adhere to vessel walls, extravasate
into a foreign tissue site, and adapt, survive, and proliferate in their newmicroenvironment (Fidler,
2003).
The potential for mobilization and invasion are critical to the process of intravasation. Cells
should be able to degrade the extracellular matrix (ECM) and secrete proteolytic enzymes to
facilitate migration and intravasation into the circulatory system. These epithelium-derived cancer
cells are thought to undergo a morphological change of epithelial-to-mesenchymal transition
(EMT; Leber and Efferth, 2009; Dhamija and Diederichs, 2016). At metastatic sites, neoplastic
cells should also infiltrate the endothelium in order to colonize new tissues and be able to
induce neo-angiogenesis to ensure sufficient blood supply to the newly formed tumor in order to
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maintain metabolic needs (Leber and Efferth, 2009; Figure 1).
The preferred growth and survival of cancer cells at certain
metastatic sites is less understood, although a reverse behavioral
change, mesenchymal-to-epithelium transition (MET), is
hypothesized to take place for this to occur (Dhamija and
Diederichs, 2016).
Metastasis itself is a highly inefficient process, as each step
in the metastasis cascade may play a limiting role in disease
progression, that is—if one fails then all fails. Only few cancer
cells are able to go on to form malignant secondary tumors.
Animal studies on the kinetics of each step have shown that post-
extravasation steps create the largest barrier to metastasis. An
early report, for example, found that 80% of injected cancer cells
survive in circulation and extravasate into distant tissues, but only
1 in 40 cells formedmicrometastasis and 1 in 100micrometastasis
actually progressed to macroscopic tumors (Luzzi et al., 1998).
Further, studies found similar results, showing the high efficiency
of extravasation and survival in the circulation to be independent
of cell’s malignant potential (Koop et al., 1995, 1996; Cameron
et al., 2000). These findings suggest that the growth of circulating
tumor cells (CTCs) in a new microenvironment is a key step in
metastatic tumor formation.
Materials shed from tumors are being investigated for their
potential use in diagnosis, prognosis, and management of cancer.
CTCs, cell-free circulating tumor DNA (ctDNA), and tumor
cell produced exosomes (oncosomes) all hold promise in the
current cancer research for future clinical use in diagnosis and
management. Oncosomes, nanovesicles actively shed from most
types of cancers in large numbers, like CTCs, are a dynamic
source of information regarding the genomic characteristics from
the parent tumor of which they are release (Deneve et al., 2013;
Pantel and Alix-Panabieres, 2013; Speicher and Pantel, 2014).
Though each has their own technical challenges, these materials
are now being isolated and detected in peripheral blood of
patients with many types metastatic cancers and are leading the
way toward use of “liquid biopsies.”
CTCS IN MODERN CANCER RESEARCH
While, it is estimated that only 0.01% of CTCs have metastatic
potential, the clinical importance of CTCs in “modern cancer
research” over the past two decades has become increasingly
apparent (Zhe et al., 2011). Although the presence of CTCs
in blood could not exclusively indicate clinically significant
macro-metastases, partly due to metastatic inefficiency, it
surely indicates the presence of malignant tumors in situ.
More and more data suggests that solid tumor shedding
occurs early in disease. A recent study detected disseminated
tumor cells (DTCs) in bone marrow of a mouse breast
cancer model during pre-malignant stages, reinforcing the
idea of early spread of tumor cells to distant organs. Fast,
specific, and sensitive detection of CTCs may have potential
to enhance diagnosis, treatment, and cancer monitoring.
CTCs may additionally be exploited for genotypic and
phenotypic abnormalities representative of the tumor
in situ.
CTC detection in peripheral blood has been reported in a
number of cancer types, such as lung (Zhang et al., 2014),
metastatic breast (Riethdorf et al., 2007), prostate (Hu et al.,
2013), colorectal cancer (Kuboki et al., 2013), and gastrointestinal
and biliary cancers (Al Ustwani et al., 2012; Tsujiura et al., 2014).
Many of these cancers are diagnosed at late stages, resulting
in high rates of mortality. Advancements in CTC collection,
enrichment, and characterization have led to increased interest
in the clinical use of CTCs. Studies in various organ systems have
consistently shown that CTCs rarely exist in the blood of healthy
subjects, consolidating their utility in the clinical laboratory
(Sastre et al., 2008; Hou et al., 2013; Tsai et al., 2016), while
supporting the premise of CTCs with the potential of a powerful
biomarker.
Various available CTC detection technologies have expanded
their use from simply diagnostic markers to tools to evaluate
overall survival, risk of metastasis, and response to therapy.
Recently, using the Veridex Cell Search System, the only
FDA approved method for CTC enumeration in whole blood,
Weissenstein et al., found a strong correlation between median
overall survival in metastatic breast cancer patients with <5
CTC/7.5 ml vs. those with ≥5 CTC (p = 0.00006; Weissenstein
et al., 2012). In a review of multicenter study of 1,358 individuals,
Miller et al. found a highly significant median overall survival in
favorable CTC counts vs. patients with unfavorable CTC counts
with metastatic breast cancer, metastatic colorectal cancer, and
prostate cancer (p < 0.0001). Additionally, patients enrolled in
therapies that decreased CTC counts displayed improvements
in overall survival, pointing to the utility that CTC analysis
in the response to anti-cancer treatments holds (Miller et al.,
2010). Studies have also taken advantage of the current available
methods to correlate tumor dissemination and stage to CTC
count. Hiraiwa et al. showed that CTC counts were higher in
metastatic patients than in non-metastatic esophageal, gastric,
and colorectal cancers and were significantly correlated to
advanced tumor stages. High CTC count, defined as 2 or
more CTCs per 7.5 ml in this study, was linked to pleural
and peritoneal dissemination (Hiraiwa et al., 2008). Further,
validation in clinical settings will establish CTC detection
as a marker for sensitive and non-invasive cancer diagnosis,
treatment evaluation and prognosis.
CTC ENRICHMENT AND DETECTION
CTCs are rare cells, detected in numbers ranging from 1 to
10 s per ml whole blood, among billions of red blood cells and
millions of leukocytes. CTC detection and isolation remain being
technologically challenging (Joosse and Pantel, 2013). In the
infancy of this rapidly growing field, current CTC detection and
analysis rely mainly on various methods of enrichment.
CTC enrichment approaches exploit the unique biological
and/or physical properties of this specified tumor cell type among
vast numbers of peripheral blood cells, in order to increase
CTC recovery by many orders of magnitude. Immunoaffinity
platforms select for CTCs based on the expression of specific
surface antigens, through either positive or negative selection.
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FIGURE 1 | The Sequential Process of Cancer Metastasis. Metastasis is a complex multi-step process. Tumor cells undergo remarkable morphological and
phenotypical changes enabling migration and infiltration of adjacent sites as single cells or small clusters. An initial epithelial-to-mesenchymal transition (EMT) allows
cells to acquire mesenchymal properties essential for motility and migration. Upon infiltrating local stroma, cancer cells intravasate into the vascular or lymphatic
system and circulate throughout the body as circulating tumor cells (CTCs). In the circulation, disseminated CTCs must overcome barriers such as sheer-stress and
the immune system. CTCs that survive the circulation extravasate and invade distant tissues by reestablishing characteristics of their corresponding primary tumor.
CTC plasticity allows them to undergo the mesenchymal-to-epithelial transition (MET) to achieve this. Each step in this metastasis cascade is rate-limiting. Cells that
successfully adapt to their microenvironment and resume proliferation successfully form overt secondary tumors. Alternately, cells that do not survive undergo cell
death.
Since most carcinomas express epithelial markers, epithelial
cell adhesion molecule (EpCAM) is most commonly used in
antibody-based positive selection with commercial technologies.
Negative selection depletes other mononucleated cells through
anti-CD45 antibody use. Established collection methods have
employed these proteins to attract and adhere CTCs to columns,
microposts, or magnetic apparatus (Alix-Panabières and Pantel,
2014).
Two early platforms, magnetic-activate cell sorting system
(MACS), and Dynabeads use magnetic fields for attract CTCs
to anti-EpCAM antibody coated magnetic microbeads (Nagrath
et al., 2016). Similarly, CellSearch (Janssen Diagnostics)
uses anti-EpCAM conjugated ferrofluid nano-particles to
immunomagnetically capture CTCs, which may then be
differentiated from contaminating leukocytes based on positive
cytokeratin or EpCAM staining and negative CD45 staining
(Hayes et al., 2006). Despite much progress in platform
development, CellSearch remains the only FDA approved
method of whole blood CTC enrichment and enumeration.
Another platform, MagSweeper (Stanford University), uses
magnetic rods, stirred through diluted blood samples, to
attract CTCs pre-labeled with EpCAM-magnetic beads (Talasaz
et al., 2009). This platform was one of the first to enrich
CTCs with a notably higher purity than its predecessors.
Importantly, it has the ability to isolate live CTCs without
perturbing gene expression throughout the enrichment
process, providing viable CTCs for analysis (Krebs et al.,
2014).
Microfluidic devices, which allow separation of CTCs,
from small fluid volumes under laminar flow, are promising
technologies. Nearly 10 years ago, Nagrath et al. was able
to selectively and efficiently isolate CTCs from whole blood
of 115/116 (99%) cancer patients using anti-EpCAM-coated
posts with this “CTC-Chip” platform, eliminating the need for
pre-labeling or sample processing (Nagrath et al., 2007). New
microfluidic approaches have appeared since then, including
methods taking advantage of physical properties as well, making
the platform applicable to isolation of CTCs that lack or have
down regulated EpCAM expression (Stott et al., 2010; Ozkumur
et al., 2013).
Positive and negative CTC enrichment is also tested based on
physical properties alone. Tumor cells and CTCs are generally
thought to be larger (>8µm) than hematologic cells (Vona et al.,
2000, 2004; Hosokawa et al., 2013). Size-based filtration methods,
such as isolation by size of epithelial tumor cells (ISET) through
membrane filters with size exclusive pores, have been previously
used to isolate individual CTCs and achieved higher sensitivity
than CellSearch (Hofman et al., 2011; Hou et al., 2011).
As CTCs extravasate and intravastate the circulation, they
undergo massive deformations in their structure due to
mechanical forces which they endure. Cancer cells are known to
be more deformable than normal cells, a quality that is correlated
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to their metastatic potential and is exploited by some enrichment
platforms (Byun et al., 2013; Park et al., 2016). Additionally,
platforms utilizing tumor cell property differences in electrical
charge and density have been reported (Müller et al., 2005; Fabbri
et al., 2013; Yoo et al., 2016).
While many of the platforms available have been able to detect
CTCs in blood samples, these small peripheral blood collections,
of several milliliters, may not be representative of the of the entire
patient blood volume. Recently, an antibody coated medical wire
(CellCollector; Gilupi GmbH) capable of detecting EpCAM and
cytokeratin positive CTCs in vivo was introduced. In a recent
study, a 30 min incubation period, in which the wire was exposed
to circulating blood in the arm vein of lung cancer patients,
showed over a 2-fold increase in CTC detection in comparison
to CellSearch (Gorges et al., 2016b). Further, efforts to enhance
the biocompatibility of these wire coatings, have been employed
to maximize functionality for downstream processes such as
sequencing analyses of captured cells (Scherag et al., 2017).
Once enriched, CTCs are detected/confirmed through various
techniques. Immunocytological and molecular approaches are
the most commonly employed. Immunocytochemistry (ICC)
may differentiate CTCs from contaminating cells through
biomarker detection. Such biomarkers can be specific for nuclear
content, epithelial proteins (i.e., cytokeratins), and hematopoietic
markers (i.e., CD45). A common immunocytological CTC
definition, currently used by CellSearch and other platforms,
is a Nucleus+/CK+/CD45− cell. However, it should be noted
that CTC designation depending primarily on epithelial marker
expression may lead to false negatives by failing to detect
CTCs that have undergone EMT (Lustberg et al., 2012). As cell
phenotypes can vary in different malignancies, the heterogeneity
of CTCs pose barriers to efficient and thorough detection by
liquid biopsies.
Reliance on epithelial markers, which most epithelial
carcinomas express, for enrichment and identification, fails to
capture subpopulations of CTCs, such as mesenchymal cells,
that may harbor clinically important information. Currently,
cancer studies in breast and prostate have already demonstrated
that mesenchymal marker expression by CTCs is associated
with poorer survival (Aktas et al., 2009; Yokobori et al., 2013).
Recently, negative depletion strategies that enrich CTCs in
phenotype-independent ways have been introduced in an effort
to solve this problem and enhance detection. Immunostaining of
CD45 and cell sorting with flow cytometry was used to enrich
the breast cancer CTC population (Lara et al., 2004). Multi-
marker Immunomagnetic Negative Depletion Enrichment of
CTCs (MINDEC), relies on depletion of non-CTCs as opposed
to targeting specific properties of CTCs (Lapin et al., 2016).
This technique is based on a multi-marker antibody cocktail
(CD45, CD16, CD19, CD163, and CD235a/GYPA) to target
various contaminating blood classes. This technique has shown
high enrichment efficiency of both epithelial and mesenchymal
CTCs, with better hematopoietic depletion than CD45 alone.
Additional, novel cell surface marker-independent techniques
have been shown to effectively detect CTCs in epithelial and
non-epithelial malignancies in the absence of cell surface tumor
markers. For example, a novel method introduced by Zhang
et al., selectively labeled CTCs through GFP expression in human
samples and cancer cell lines transfected with tumor selective
replicating HSV-1 with a high detection efficiency (Zhang et al.,
2016).
Table 1 shows various CTC isolation methods used in the last
few years.
Newer methods have employed combinations of epithelial,
mesenchymal, tumor-specific, and tissue-specific marker
expression (Pantel and Alix-Panabieres, 2013).
Additionally, nucleic acid-based technologies have provided
an alternate avenue (Yu et al., 2011), as improvements in non-
fixating enrichment procedures have allowed for the use of RT-
PCR and qRT-PCR to amplify single or multiple gene transcripts
for CTC detection.
Most recently, emerging single-cell sequencing techniques
have shifted the field toward individual CTC analysis of
genetic alterations associated with tumor mechanisms, clinical
outcomes, therapy response, and drug targets and resistance.
The usefulness of genomic analyses, however, is limited by
heterogeneity between cancer subtypes, presenting barriers
toward finding universal markers. Similarly, all the current
enrichment, detection, and analysis techniques available harbor
their own technical challenges and limitations. Most of these are
outside the scope of this discussion.
CTCS IN PANCREATIC CANCER
DIAGNOSIS
Pancreatic cancer is one of the deadliest malignancies. Pancreatic
ductal carcinoma (PDAC) makes up the majority of pancreatic
cancers. While advancements in the treatment of other cancer
typesmay have led to significant improvement in patient survival,
advancements in pancreatic cancer research have not been met
with the same success. PDAC incidence has remained stable over
the last 30 years and the lack of fruitful therapies and new/useful
diagnostic methods have yet to be changed in pancreatic cancer
(Ryan et al., 2014). With current therapies improving survival
outcomes by only a few months, pancreatic cancer patients
face a 5 year survival rate of only 7%. Gemcitabine, the
first-line of PDAC therapy, only modestly improves survival
in advanced pancreatic cancer, while the clinical benefit of
combinational-targeted therapies (Erlotinib+Gemcitabine) has
proven to have only slight benefit, increasing overall survival
by less than a month (Burris et al., 1997; Moore et al., 2007).
Recent work in combinational chemotherapeutics has led to
a promising approach, FOLFIRINOX (Oxaliplatin, Irinotecan,
Leucovorin, and 5-fluorouracil), which has almost doubled
survival inmetastatic pancreatic adenocarcinoma patients to 11.1
months compared to 6.8 months with single-agent gemcitabine
(Conroy et al., 2011). In another promising approach, albumin
bound paclitaxel (Abraxane) plus standard gemcitabine therapy
increased overall survival to 8.5 months compared to standard
gemcitabine therapy with an overall survival of 6.7 months
(Von Hoff et al., 2013). The toxicity associated with these
regimens is unfavorable and should be used in patients with good
performance status. Unfortunately, 5 year survival rates remain
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TABLE 1 | CTC isolation techniques.
CTC isolation method Disease Comment References
Size-based filtration method: Use of membrane filters with
size exclusive pores
Multiple carcinomas Isolation of CTCs based on cell
size to isolate them from
leukocytes
Vona et al., 2000, 2004;
Hosokawa et al., 2013
Veridex cell search system: Anti-EpCAM antibody coated
microbeads
Multiple carcinomas The only FDA approved Allard et al., 2004
Magnetic-activated cell sorting system (MACS) Breast cancer Enrichment of the CTC
population
Lara et al., 2004
Use of electrical charges and density properties of cancer
cells
Primary breast cancer CTCs detected in 8.3% of
patients before surgery. After
Chemotherapy, CTCs detected
in 44% of previously negative
patients
Müller et al., 2005
Cell Search System Gastro-intestinal
cancers
High CTC number corrected with
metastasis and with low survival
Hiraiwa et al., 2008
MagSweeper: Magnetic rods Metastatic breast
cancer
Higher purity than the Cell search
system
Talasaz et al., 2009




Isolate CTC with down regulated
EpCAM
Stott et al., 2010; Ozkumur
et al., 2013
Combination of epithelial and mesenchymal markers: Use





Avoid CTC phenotype problem Deneve et al., 2013










Lapin et al., 2016
GILUPI cell collector: cell Collector-Wire coating: EpCAM
and Cytokeratin antibody coated medical wire
Lung cancer Isolation of CTCs from peripheral
blood to overcome the blood
volume limitations
Gorges et al., 2016b
Wire coating enhanced: Enhanced wire coting to maximize
functionality
Breast cancer cells Improvement of the wire
technology
Scherag et al., 2017
relatively unchanged. It is estimated that by 2030 pancreatic
cancer will be the second leading cause of cancer-related deaths
(Rahib et al., 2014; Dawson and Fernandez-Zapico, 2016).
The idea of a liquid biopsy, which could reveal diagnostic and
prognostic information about a patient’s state, has been gaining
much traction in the past 10 years. In one of the earliest studies,
with 12 types of metastatic carcinomas in 964 patients, CTCs
were successfully detected in patients with pancreatic cancer
using CellSearch, albeit in lower numbers than the other cancers
(Allard et al., 2004). Below, we summarize the studies of CTCs
in the diagnosis, staging, and prognosis for pancreatic cancer
patients.
Pancreatic cancer is a fast progressive disease and its early
diagnosis is challenging. Initial pancreatic cancer diagnosis
depends largely upon symptoms, which would only appear
late when tumor have fully progressed and are not specific
to be recognized at early stages. Due to the pathobiology and
aggressiveness of PDAC, by the time anorexia, early satiety, pain,
and weight loss start present, the disease has already progressed,
leaving little room for a favorable prognosis. Additionally, of the
15% of patients seeking medical care 6 months prior to diagnosis,
25% have symptoms resembling upper abdominal disease that
may lead tomisdiagnosis (DiMagno, 1999). Affirmative diagnosis
is made by tissue biopsies obtained by surgery, image guided CT
biopsy, or fine needle aspiration through endoscopic ultrasound
(EUS-FNA). Despite its widespread use, EUS-FNA does have
diagnostic drawbacks, specifically a sensitivity range from 75
to 94% and a specificity of 78 to 95%, with low but lethal
complications such as pancreatitis and bowel perforation (Court
et al., 2015; Bournet et al., 2016). For CTC detection to be
adopted to pancreatic cancer diagnosis, it must be useful for
early diagnosis and/or monitoring treatment responses. A key
performance milestone necessary for the implementation of CTC
technologies is an understanding of disease stage at which CTCs
can be detected. At the same time, it should be kept in mind
that CTC research in pancreatic cancer is at nascent stage, while
CTC detection methods and criteria vary largely between studies.
It is important to critically analyze the markers available and to
characterize CTCs at different stages of cancer progression.
CTC detection has been explored in early diagnosis of various
cancers and CTCs have been detected prior to tumor detection
by traditional methods. A recent study, for instance, found that
CTCs could be detected 1–4 years before lung cancer became
detectable through CT-scan screening in the same patients (Ilie
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et al., 2014). For breast cancer, the American Society of Clinical
Oncology (ASCO) has already approved the use of CTCs as a
tumor marker, creating new directions for early breast cancer
diagnosis (Harris et al., 2007).
Similar results have been obtained in pancreatic cancer. In a
mousemodel of PDAC, Rhim et al. found that inflicted pancreatic
cells underwent EMT early during cancer development. These
cells with EMT were predicted to represent early cancer cells, as
the extent of EMT correlated well to invasive properties in tumor
cells, facilitated their intravasation to circulating the blood and
hepatic seeding, prior to the manifestation of primary tumors
(Rhim et al., 2012). Additionally, blood samples from patients
with pancreatic cystic lesions were detected to contain pancreas
epithelial cells, at a time prior to cancer diagnosis. These findings
suggested that pancreatic cell appearance in circulating blood
precedes in situ tumor formation, and detection of CTCs could
be an early biomarker for PDAC early diagnosis.
CTC-specific gene expression has been explored as surrogate
markers for early cancer detection. Such studies mostly detect
CTCs via detecting their expression of epithelial proteins.
Reverse transcription-coupled polymerase chain reaction (RT-
PCR) could be used to examine potential epithelial markers
in CTCs derived from tumors of the epithelia. Soeth et al.,
evaluated cytokeratin 20 (CK20) detection, through RT-PCR
detection from themarrow and venous blood in pancreatic ductal
carcinoma patients. CK-20 positivity was detected in cells of
52 of 154 patients in venous blood, where higher CK20 level
was correlated to UICC-tumor stage (Soeth et al., 2005). In
a study of 34 pancreatic cancer patients prior to treatments,
de Albuquerque et al used immunomagnetic enrichment for
CTCs in peripheral blood based on mucin-1 and EpCAM
expression. Subsequently, multi-marker RT-PCR analysis was
used to detect tumor-associated transcripts, including KRT19,
MUC1, EpCAM, CEACAM5, and BIRC5. CTCs with at least
one marker in peripheral blood were detected in 47.1% patients
prior to undergoing treatment (de Albuquerque et al., 2012).
Detection efficacy was increased with the use of multiple markers
as opposed to single marker use, indicating differential gene
expression among CTCs from the same cancer patient.
Zhang et al., used an alternative strategy by enriching and
identifying CTCs through a combination of CD45 and CK with
a FISH-CEP8 probe in 22 pancreatic cancer patients. CTCs
were detected from 15 of the patients, with CTCs ranging
from 0 to 60 cells/3.75 ml of blood. In comparison, healthy
controls, and patients with benign pancreatic tumors were
negative for detection of CTCs, and sensitivity and specificity
of CTC detection in pancreatic diagnosis were determined to
be 68.18 and 94.87%, respectively, when using 2 cells/3.75 ml
as cutoff. CTC-positive patients exhibited metastasis and poorer
survival rates upon a 1.5 year follow-up. CTC positivity did
not correlate significantly to CA19-9 levels of the in situ tumor.
It is well-known that, though CA19-9 has a high sensitivity
and specificity in advanced pancreatic cancers, its diagnostic
usefulness is questionable to diseases at early asymptomatic
stages. The combination of CA19-9 and CTC positivity in the
study above increased detection rates from 68.18 to 77.3% (Zhang
et al., 2015). The results from this study suggest CTCs as
biomarkers for the diagnosis of early stage pancreatic cancers, in
asymptomatic patients, and from patients with normal CA19-9
plasma levels. A later study by Xu et al., used a similar approach
in 40 patients and dramatically high detection rates in PC patients
(90%). Diagnostic rates increased to 97% when combining CTC
≥ 2 and CA19-9 > 37 µmol/L as a cutoff. Identification of
chromosomal instability in CTCs, characterized as chromosome
8 triploids, showed a significantly statistic prognostic correlation.
Patients with triploid CTCs < 3 displayed both higher 1 year and
overall survival compared to those with ≥ 3 (Xu et al., 2017).
Doublecortin-like kinase 1 (DCLK1) may be another marker
for CTC detection in early PDAC stages. Prior work suggests
that Dclk1 marks stem cells, being able to differentiate cancer
from normal stem cells. Interestingly, this marker protein is
overexpressed in pancreatic and colorectal cancers (Nakanishi
et al., 2012; Bailey et al., 2014). Qu et al., found elevated serum
DCLK1 levels in stage I and II PDAC patients relative to controls
and a decline in stage III and IV patients to levels similar to those
seen in control patients. Diagnostic utility analysis showed both
DLCK1 sensitivity and specificity to be significant in stage I and
II patients. Furthermore, the investigators evaluated DCLK1 in
the KPC mouse model, finding the serum DCLK1 levels to be
significantly elevated as early as 5 weeks in KPC mice, compared
to control mice. Over 50% of CTCs isolated from KPC mice
whole blood were DLCK1+, suggesting a possible biomarker to
be used in conjunction with CTCs for detection of early stage
pancreatic cancer (Qu et al., 2015).
Kulemann et al., investigated the usefulness of CTC detection
in pancreatic cancers from both localized and advanced stages.
Peripheral blood from PDAC patients was used to capture
CTCs for cytological and KRAS mutational analysis using the
ScreenCell isolation method (Kulemann et al., 2015). High
CTC detection efficiency as low as 2 cells/ml was calibrated
by spiking experiments with healthy donor blood. CTC KRAS
mutations were identified in 8 of 11 PDAC patients (73%).
This is in sharp contrast to conventional biopsy-based diagnosis
for the same patients, by which 2 of 11 samples (18%) were
cytologically categorized as negative/non-diagnostic, while the
rest exhibited abnormal morphology (18%) or were categorized
as suspicious (64%). Moreover, the authors found no difference
in the detection rate between early and advanced diseases,
suggesting that CTCs are disseminated from primary tumors
early in disease development and can be used to diagnose
pancreatic cancer at initial stages where curative surgery may be
available. It should be pointed out that this finding is contrary
to those shown by Soeth et al. (2005), in which significant stage
dependent differences were observed in CTC detection. Further
studies are needed to clarify whether the difference is due to the
differences in CTC detection strategies.
CTCS IN METASTASIS AND EARLY
CANCER
Early local invasion and metastasis are prominent factors in the
poor prognosis of pancreatic cancer, as most patients are found
withmetastatic disease at diagnosis (DiMagno et al., 1999; Pandol
Frontiers in Physiology | www.frontiersin.org 6 June 2017 | Volume 8 | Article 381
Pimienta et al. Circulating Tumor Cells in Pancreatic Cancer
et al., 2009). The impact of CTCs on pancreatic cancer metastasis,
recurrence, and prognosis has been investigated.
A recent 9-cohort meta-analysis of separate studies using
CellSearch and RT-PCR detection methods, involving 623
pancreatic cancer patients altogether, revealed associations
between CTC detection and poor prognosis. Out of 623 patients,
268 (43%) were classified as CTC positive and displayed poor
progression-free survival and worse overall survival than those
in the non-CTC group (Han et al., 2014).
Using the CellSearch enrichment method, Kurihara et al.,
investigated the utility of CTCs in peripheral blood as a marker
of clinical outcomes in 26 patients with pancreatic cancer. CTC
positivity was found in 11 of 26 pancreatic cancer patients (42%).
The authors demonstrated a significant difference in median
survival times between CTC positive and negative patients, for
110.5 and 375.8 days, respectively (P < 0.001; Kurihara et al.,
2008). Given that the detection method was shown to have 100%
specificity, with no CTCs detected in the non-cancer groups,
CellSearch detection strategy may not be sensitive enough, as
no CTCs were detected from the other 58% pancreatic cancer
patients. These results suggest the need of developing more
sensitive methods to detect positive CTCs in all pancreatic cancer
cases.
Similarly, de Albuquerque et al found a correlation between
CTC positivity (47% of patients) and median progression-
free survival (PFS). Patients with at least one tumor-associated
transcript found in their CTCs, enriched from peripheral
blood using immunomagnetic EpCAM and mucin 1 detection,
had a PFS of 66.0 vs. 138.0 days in those who did not.
Intriguingly, CTC enumeration was found to have no correlation
to clinicopathological features of the disease, includingmetastasis
status and tumor stages (de Albuquerque et al., 2012).
Bidard et al. studied CTC detection rates in a subset of 79
patients with locally advanced pancreatic carcinoma enrolled
in the LAP 07 trial. The primary study (LAP 07) assessed
the effect of subsequent chemotherapy vs. chemo-radiotherapy
continuation on overall survival in patients whose disease was
controlled after 4 months of chemotherapy alone. The patient
subgroup was screened for CTCs using CellSearch technology
prior to chemotherapy administration and 2 months after
treatment. While the investigators found that CTC positivity
was not prognostic of PFS, they found it to be an independent
prognostic factor associated with poor tumor differentiation and
shorter overall survival (Bidard et al., 2013).
Bissolati et al., used the same CellSearch technique with
systemic and portal vein blood of 20 patients undergoing
pancreatic resection. No significant differences in both overall
survival and disease-free survival between CTC-positive and
-negative groups. The authors did, however, find a higher
incidence of liver metastasis upon a 2 and 3 year follow up in
the CTC-positive portal vein group (Bissolati et al., 2015).
Similarly, an early study investigated CTC positivity in 67
intraoperative patients with biliary-cancer. Molecular detection
of CEA mRNA-positive CTCs from peripheral, central, and
portal veins via RT-PCR was associated with a significant
incidence of hematogenous metastases compared to CTC-
negative patients (37.5 vs. 11.4%; Uchikura et al., 2002).
Nonetheless, whether surgical resection of the pancreas itself
may contribute to tumor cell shedding remains to be addressed.
Pancreaticoduodenectomy (PD), involving the pancreatic head,
and distal pancreatosplenectomy (DPS), involving the pancreatic
body and tail, are standard surgical procedures. Both require
necessary mobilization of the pancreas, and may lead to CTC
dissemination via the portal vein to increase the risk of liver
metastasis (Kuroki and Eguchi, 2017).
Table 2 represents data showing association between CTC
presence and pancreatic cancer stage and outcome.
Chausovsky et al., used RT-PCR to examine the usefulness
of CK20 expression in CTCs in the diagnosis of metastatic
lung, stomach, colon, and pancreatic cancers (Chausovsky et al.,
1999), since CK20 has been shown to not be transcribed
in cells of hematopoietic lineage (Burchill et al., 1995).
Chausovsky concluded that CK20 is a potential biomarker for
detecting metastasis, with a sensitivity of 22/28 (78.6%) in
patients with metastatic pancreatic cancer. Cytokeratins are used
conventionally to characterize cancer cells of epithelial origin
(Cooper et al., 1985; Lane and Alexander, 1990). Combination
of cytokeratin and additional gene expression may improve the
efficacy of CTC detection.
Poruk et al., assessed the potential of CTCs as biomarkers
in 50 patients prior to surgical resection, based on EMT-related
epithelial and mesenchymal marker expression. CTCs were
acquired from blood samples through the method of ISET. CTCs
were further identified by immunofluorescence staining with
antibodies against pan-cytokeratins and the mesenchymal cell
protein, vimentin. This analysis found that 78% of patients had
CTCs expressing cytokeratin and 67% co-expressed vimentin,
while no CTCs were found to express vimentin only. The
authors found a significant association between cytokeratin only
positive CTCs and worse survival. Interestingly, co-expression
of vimentin was predictive of recurrence (p = 0.01). Of the
patients diagnosed with metastatic cancer at the time of surgery,
all the CTCs were positive for dual staining (Poruk et al., 2016).
These findings indicate the involvement of EMT mechanism in
metastatic progression. EMT would render CTCs heterogeneous
andmulti-marker analysis would have to be employed in order to
ensure a comprehensive detection of all CTCs in a patient blood
sample.
A recent study enumerated CTCs independently of surface
marker status using a GFP expressed tumor selective Herpes
Simplex Virus replicated based on telomerase activity.
Transfected cells of 290 samples of patients with different
solid tumors were examined and CTCs were detected in patients
with epithelial and non-epithelial tumors from as little as 4 ml
of blood. PC patients had a positive CTC detection rate of 88.2%
across various stages and had the highest average number of
cells identified per samples (43.1). Additionally, CTC detection
rates increased to 100% in PC patients with regional lymph node
metastasis but no distant metastasis (N+M0), further supporting
the use of CTCs as a biomarker in disease progression (Zhang
et al., 2016). Other recent phenotypic-independent enrichment
platforms have shown some success in CTC enumeration
regardless of epithelial or mesenchymal surface proteins.
Negative selection of hematopoietic cells in blood samples of
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TABLE 2 | Association between CTC presence and disease stage and outcome.
References Finding Number of patients CTC Detection method in pancreatic cancer patients
Allard et al., 2004 First detection of CTC in pancreatic cancer
biopsies
16 Cell search
Soeth et al., 2005 Higher CK20 in the blood correlated with tumor
stage
154 CK20 RT-PCR
Kurihara et al., 2008 Association between presence of CTC and
survival
26 Cell Search
de Albuquerque et al.,
2012
Association between presence of CTC and
decreased PF survival. No association between
presence of CTC and disease stage
34 Multi marker RT-PCR
Bidard et al., 2013 No PF survival association but association with
poorer overall survival
79 Cell Search
Han et al., 2014 Association between CTC detection and poor
prognosis
623 Cell Search and RT-PCR (9-cohort meta-analysis study)
Zhang et al., 2015 CT-positive patients exhibited metastasis and
poorer survival
22 CD45 and CK with FISH-CEP8 probe
Xu et al., 2017 Diagnostic rate increased to 97% when
combining CTC>2 and CA19-9>37
40 NE-iFISH
Kulemann et al., 2015 No correlation between CTC and stage. CTC
could be used as early marker
11 Screen Cell Isolation Method
Bissolati et al., 2015 No PF or overall survival association. But higher
liver metastasis incidence
20 Cell Search
PC patients using MINDEC showed a CTC detection rate of
71%. Further, characterization of the enriched cells showed the
presence of both epithelial and mesenchymal CTC populations.
While the high rate of positivity in this proof-of-principle study,
in comparison to previous phenotype specific platforms, could
be due to the authors use of patients with metastatic disease
only, its ability to detect both epithelial and mesenchymal cells,
in addition to CTC clusters, marks a progressive trend toward
comprehensive detection of both epithelial and mesenchymal
CTCs with one technique (Lapin et al., 2016). More importantly,
both CTC surface marker-independent enrichment techniques
allow for the viability of collected cells to be subsequently used
for downstream genetic analysis without compromise from high
background leukocyte levels.
Recent works characterizing EMT found CTCs positive for
both epithelial and mesenchymal markers in peripheral blood
of breast cancer patients (Yu et al., 2013). Studies in mouse
models have provided insight into the composition of CTCs
in pancreatic cancer. Single-cell RNA sequencing revealed the
expression of both epithelial and mesenchymal markers in KPC
LSL-KrasG12D, Trp53flox/flox or +, Pdx1-Cre (KPC) mouse
pancreatic tumors. Moreover, the authors observed substantial
loss of the classical E-cadherin expression, suggesting that
some CTCs of epithelial lineage could indeed adopt a partial
mesenchymal stromal phenotype through EMT, while retaining
other epithelial features such as cytokeratin expression (Ting
et al., 2014).
Different from epithelial cells, most mesenchymal stromal
cells harbor certain stem cell properties, being able to be induced
to differentiate into more mature cells (Zhau et al., 2011). The
EMT phenotype is usually associated with expression of cancer
stemnessmarkers (Kong et al., 2011). Compared to other cancers,
however, very little is known about stemness in pancreatic cancer
CTCs.
In breast cancer, expression of cancer stem cell markers in
CTCs is a sign of increased the metastatic ability (Papadaki et al.,
2014). The expression of cancer stemness marker ALDH1 on
CTCs was found to correlate to the stage of the disease and
to the expression of EMT markers vimentin and fibronectin in
prostate cancer patients (Raimondi et al., 2011). A study by
Barrière et al. (2012) aimed at the detection of CTCs endowed
with mesenchymal and/or stem cell characteristics, at the time of
initial diagnosis with breast cancer, found that EMT and cancer
stemness occur in the primary tumors and are associated with an
enhanced ability for tumor cells to intravasate in the early phase
of cancer development.
Multiplex transcriptome profiling of single CTCs revealed
presence of sub-populations of CTCs expressing multiple pro-
cancer transcripts including cancer stem cell markers such as
CD44 and CD24 (Gorges et al., 2016a). So far multiple markers
have been used to detect CTC stem cell properties in CTCs,
including CD44, CD133, CXCR4, ABCG2, and ALDH1. Other
markers used uniquely for pancreatic cancer CTCs include CD24
and c-Met (Yang et al., 2015). Whether CTCs with mesenchymal
or stem cell characteristics may be used as a marker for
aggressiveness of the disease remains to be evaluated in future
studies.
CHALLENGES
There has beenmuch progresses over the last decade to overcome
the initial barriers of CTC research in the laboratory and clinic.
Significant technological development has been made for CTC
detection, enrichment, and molecular characterization. On the
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other hand, CTC research in gastrointestinal cancers had a late
start relative to other human malignancies (Allard et al., 2004).
Due to gastrointestinal biology, pancreatic cancer detection via
CTCs has its own set of challenges. It is widely proposed
that the liver sequesters CTCs as they pass into the systemic
circulation via the portal vein (Jiao et al., 2009). The predominant
dissemination of pancreatic cancers to the liver have supported
this notion. A recent report detected CTCs in 100% (14/14) of
portal vein samples of patients with pancreaticobiliary cancers as
opposed to under 25% (3/14) when peripheral samples were used
for detection (Catenacci et al., 2015), a result consistent with the
notion that higher CTC numbers are detected in portal vein as
opposed to peripheral blood (Waxman et al., 2014). Furthermore,
there was a significant increase in CTC detection in portal blood
vs. peripheral blood, with a mean of 125.64 CTCs/7.5 ml as
opposed to 0.8 CTCs/7.5 ml (p = 0.01; Catenacci et al., 2015).
This study further emphasizes the importance that the collection
site plays in CTC detection.
While preliminary studies in various cancers are
demonstrating the potential of CTCs in early cancer detection,
the continuous data coming out using different platforms
(exploiting size, density, charge, surface antigens, etc.) make it
challenging to reach a consensus for clinical application. The
diversity of methods for CTC enumeration and characterization
can confuse the research and the clinical communities. There
is a lack of large studies comparing enrichment and detection
between CTC detection platforms. A pilot comparative study of
54 pancreatic cancer patients investigated differences between
CellSearch and amarker-independent ISETCTC isolation (Khoja
et al., 2012). The authors detected significantly more CTCs using
ISET in comparison to CellSearch (93 vs. 40%). Similar studies
in other cancers have pointed out the discrepancies between
platforms (Farace et al., 2011; Hofman et al., 2011).
Discrepancies can partially be attributed to different types
of carcinomas and their expression of surface markers.
Furthermore, the differences in specificity and sensitivity may
lead investigators to adapt different platforms for their specific
study. This raises many concerns in regards to the identities
of CTCs. As EMT facilitates CTCs with increased capacity for
detachment and invasion, the loss of epithelial lineage marker
expression makes the identification particularly difficult. We
must further explore the limitations that certain platforms create
in capture efficiency. For example, EpCAM expression, which
CellSearch exploits, is heterogeneous and cleavage has been
reported (Maetzel et al., 2009). Limitations of other epithelial cell
markers have also been reported, such as the down regulation of
CK20 in tumors leading to false-negatives (Vlems et al., 2002;
Krebs et al., 2014). It would be ideal for platforms to detect
bothmesenchymal and epithelial characteristics of CTCs, and the
platforms must be carefully validated.
Additionally, not only do detection rates vary by platforms,
but also between cancers. There is currently no consensus on the
cutoff value for CTC positivity, even within a single platform.
Stringent parameters should be set for CTC use not only in
detection, but also as a prognostic marker of clinical outcomes
in pancreatic cancer. Although it may be difficult due to the
differences in enrichment and detection between platforms,
standardization across single or multiple platforms is paramount
for future incorporation into the field.
Due to the complex nature of the metastatic process,
disseminated cells may be clinically silent for long durations. In
breast cancer, cytological assessment suggests that CTCs actively
undergoing mitosis are most common in late-stage disease and
have prognostic value (Adams et al., 2016). One study found
that aberrant VCAM1 expression, a common complication of
breast cancer, was crucial for the transition from dormancy to
overt metastasis (Lu et al., 2011). We must continue to explore
ways to stratify CTCs in ways that will allow us to distinguish
indolentmicrometastasis from aggressive CTCs prior to clinically
significant metastasis in pancreatic cancer patients.
CONCLUSION AND FUTURE DIRECTIONS
Literature evaluating the diagnostic and prognostic role of
CTCs in cancer is continuously being reported. Many studies
in different malignancies have shown clear associations of
CTCs with clinical cancer progression. Much of the current
research is now shifting to CTC characterization in order to
select appropriate therapies for individuals based on the gene
signatures of the CTCs and to measure response to therapies.
For example, CTC count now outperforms traditional response
evaluation methods in patients with metastatic castration-
resistant prostate cancer (Onstenk et al., 2016). With reports
estimating the half-life of CTCs to be on the order of hours, their
detection can provide a current representation of the malignancy
(Meng et al., 2004; Stott et al., 2010).
Future investigations should thoroughly explore CTC
response to pancreatic cancer treatments. Furthermore, ex vivo
CTC culture and expansion experiments can improve our
understanding of the mechanisms of dissemination and escape
from dormancy. Single-cell sequencing with next-generation
sequencing platforms is paving the way toward understanding
the genetic makeup of CTCs and the clinical significance of their
genomic alterations (Alix-Panabières and Pantel, 2014). A recent
study in a pancreatic cancer mouse model used single-molecule
RNA sequencing of CTCs to identify Wnt2 as an up-regulated
gene in pancreatic cancer CTCs, which is implicated in cell-
death suppression and cancer dissemination. In addition, the
authors observed the same Wnt2 signaling aberrations in CTCs
of 5/11 patients with metastatic pancreatic cancer (Yu et al.,
2013). Such studies have the potential to improve our current
clinical management, especially ones exploring new drug targets
involved in cancer spread. CTC use as a biomarker is currently
being investigated in over 360 open clinical trials registered on
ClinicalTrials.gov (Alix-Panabières and Pantel, 2014).
Considering that methods have been developed that have
the possibility of being used in the diagnosis, stratification of
patients and monitoring of therapy, next efforts require a focus
on validation of leading methods for aiding clinical care. For the
methods chosen, the validation of the method for certification in
clinical use followed by well-designed studies to show utility of
the method in the clinical setting are necessary for approval of
test for clinical application.
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There are challenges in the pancreatic cancer field for
development of a test that has utility in early diagnosis or choice
of chemotherapy. For example, in the area of early diagnosis,
a population at increased risk is needed to show performance
of the method in detecting pancreatic cancer at an earlier
stage than that achieved with current approaches. Currently, the
Consortium on Chronic Pancreatitis, Diabetes, and Pancreatic
Cancer (CPDPC) in the United States is developing a protocol
for this purpose choosing patients with diabetes after age 50
as the best high risk group to use to identify early diagnostic
biomarkers (http://cpdpc.mdanderson.org). Because about 1% of
these patients will be found to have pancreatic cancer over 3
years after the diagnosis of diabetes, the CPDPC has determined
that the study will require enrollment of 10,000 subjects. At
present, the inclusion of measurement of CTCs is not being
considered because of the technical difficulties involve with CTC
measurements. On the other hand, once a proteomic, ctDNA
and/or RNA technique is developed to identify patients with early
pancreatic cancer, measurements of CTCs can be applied to this
group for further characterization including choice of therapy.
Similarly, it is difficult to apply CTC technology to the
choice of chemotherapy as the current therapies do not have
a significant effect on long term survival. One the other hand,
surgery does have significant effects on long term survival
in a substantial percentage of patients. Thus, it seems that
currently the best situation to develop a validated test for CTC
measurements uses patients who are candidates for curative
surgery. Hypotheses to be tested should focus on the role of
CTCmeasurements in predicting the outcome of curative surgery
and early demonstration of disease recurrence. Certainly, studies
that show performance of CTC measurements in determining
and monitoring outcome in surgical patients will have important
impacts in disease management and are much more feasible than
studies designed for early diagnosis.
Another area of significant importance in the field is the
determination of the biology of CTCs. As these cells represent
the metastatic process which is the key determinant of poor
outcome in pancreatic cancer patients, a better understanding
of the biology of these cells will be central to advancing our
treatments. Are there unique mechanisms in pancreatic cancer
that account for its high rate ofmetastasis? Are there properties of
pancreatic cancer CTCs that account for its resistance to therapy?
Exploring these questions will require advancing the methods
of isolation and propagating these cells so that the biologic
experiments including observing their behavior in cell culture
and animal models can be performed.
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